End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
100.6 EUR | -0.40% |
|
+1.28% | -8.54% |
20/06 | Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors | CI |
12/06 | Zimmer Biomet Enters Co-Marketing Deal With RevelAi Health | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an enterprise value anticipated at 3.43 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.54% | 22.33B | - | ||
-5.60% | 181B | C+ | ||
-4.45% | 101B | C | ||
-4.15% | 67.54B | A | ||
-8.63% | 45.09B | B- | ||
+9.70% | 44.37B | B- | ||
+6.13% | 40.7B | B+ | ||
+15.22% | 29.85B | B | ||
+14.80% | 24.49B | A- | ||
-6.46% | 23.99B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZBH Stock
- ZBH Stock
- Ratings Zimmer Biomet Holdings, Inc.